Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Gómez-Caamaño A[au]:

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher FR et al. Nat Genet. (2018)

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Dadaev T et al. Nat Commun. (2018)

Demand for radiotherapy in Spain. Rodríguez A et al. Clin Transl Oncol. (2017)

Search results

Items: 45

1.

A Model of Indirect Cell Death Caused by Tumor Vascular Damage after High-Dose Radiotherapy.

Rodríguez-Barbeito P, Díaz-Botana P, Gago-Arias A, Feijoo M, Neira S, Guiu-Souto J, López-Pouso Ó, Gómez-Caamaño A, Pardo-Montero J.

Cancer Res. 2019 Dec 1;79(23):6044-6053. doi: 10.1158/0008-5472.CAN-19-0181. Epub 2019 Oct 22.

PMID:
31641030
2.

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.

Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium.

Radiother Oncol. 2019 Sep;138:59-67. doi: 10.1016/j.radonc.2019.04.034. Epub 2019 May 27.

3.

Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy.

Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML.

J Natl Cancer Inst. 2019 May 16. pii: djz075. doi: 10.1093/jnci/djz075. [Epub ahead of print]

PMID:
31095341
4.

Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.

Büchser D, Casquero F, Espinosa JM, Perez F, Minguez P, Martinez-Indart L, Suarez F, Gonzalez A, Cacicedo J, San Miguel I, Maleta A, Gomez-Caamaño A, Bilbao P, Gomez-Iturriaga A.

Radiother Oncol. 2019 Jun;135:13-18. doi: 10.1016/j.radonc.2019.02.018. Epub 2019 Mar 5.

PMID:
31015158
5.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
6.

Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes.

González-San Segundo C, Jové J, Zapatero A, Pastor-Peidro J, Vázquez ML, Casaña M, Mengual JL, Gómez-Caamaño A, Gómez-Iturriaga A, Vallejo C, Henríquez I, Muñoz-García JL, Clemente J, Porras M, Collado E, Ossola G, Villafranca E, Cabeza MA, López-Torrecilla J.

Clin Transl Oncol. 2019 Aug;21(8):1044-1051. doi: 10.1007/s12094-018-02021-7. Epub 2019 Jan 7.

PMID:
30617939
7.

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.

Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A; Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR).

Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6.

PMID:
30293231
8.

Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist.

Couñago F, Artigas C, Sancho G, Gómez-Iturriaga A, Gómez-Caamaño A, Maldonado A, Caballero B, López-Campos F, Recio M, Del Cerro E, Henríquez I.

Rev Esp Med Nucl Imagen Mol. 2018 Sep - Oct;37(5):302-314. doi: 10.1016/j.remn.2018.07.005. Epub 2018 Aug 20. Review. English, Spanish.

PMID:
30139594
9.

Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- Ain't no mountain high enough…. to keep me getting to you.

Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Igrutinovic I, Videtic G.

Lung Cancer. 2018 Sep;123:172-173. doi: 10.1016/j.lungcan.2018.06.016. Epub 2018 Jun 18. No abstract available.

PMID:
29921448
10.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

11.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

12.

Advanced Imaging Techniques in Evaluation of Colorectal Cancer.

García-Figueiras R, Baleato-González S, Padhani AR, Luna-Alcalá A, Marhuenda A, Vilanova JC, Osorio-Vázquez I, Martínez-de-Alegría A, Gómez-Caamaño A.

Radiographics. 2018 May-Jun;38(3):740-765. doi: 10.1148/rg.2018170044. Epub 2018 Apr 20. Review.

PMID:
29676964
13.

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.

Jeremić B, Casas F, Dubinsky P, Gomez-Caamano A, Čihorić N, Videtic G, Igrutinovic I.

Front Oncol. 2018 Feb 20;8:30. doi: 10.3389/fonc.2018.00030. eCollection 2018. Review.

14.

Radiation Therapy in Extensive Stage Small Cell Lung Cancer.

Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, Filipovic N.

Front Oncol. 2017 Aug 11;7:169. doi: 10.3389/fonc.2017.00169. eCollection 2017. Review.

15.

Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.

Hervás A, Gómez-Caamaño A, Casaña M, Gómez-Iturriaga A, Pastor J, Jove J, Mengual JL, Gónzalez-San Segundo C, Muñoz J.

Clin Transl Oncol. 2018 Feb;20(2):193-200. doi: 10.1007/s12094-017-1709-z. Epub 2017 Jun 30.

PMID:
28667448
16.

Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.

Ruiz-Bañobre J, Pérez-Pampín E, García-González J, Gómez-Caamaño A, Barón-Duarte FJ, López-López R, Vázquez-Rivera F.

Lung Cancer. 2017 Jun;108:217-221. doi: 10.1016/j.lungcan.2017.04.007. Epub 2017 Apr 14. Review.

PMID:
28625638
17.

Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?

Jeremic B, Casas F, Dubinsky P, Gomez-Caamano A, Cihoric N, Videtic G, Latinovic M.

J Radiat Res. 2017 May 1;58(3):267-272. doi: 10.1093/jrr/rrx003.

18.

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.

Kerns SL, Dorling L, Fachal L, Bentzen S, Pharoah PD, Barnes DR, Gómez-Caamaño A, Carballo AM, Dearnaley DP, Peleteiro P, Gulliford SL, Hall E, Michailidou K, Carracedo Á, Sia M, Stock R, Stone NN, Sydes MR, Tyrer JP, Ahmed S, Parliament M, Ostrer H, Rosenstein BS, Vega A, Burnet NG, Dunning AM, Barnett GC, West CM; Radiogenomics Consortium.

EBioMedicine. 2016 Aug;10:150-63. doi: 10.1016/j.ebiom.2016.07.022. Epub 2016 Jul 20.

19.

Demand for radiotherapy in Spain.

Rodríguez A, Borrás JM, López-Torrecilla J, Algara M, Palacios-Eito A, Gómez-Caamaño A, Olay L, Lara PC.

Clin Transl Oncol. 2017 Feb;19(2):204-210. doi: 10.1007/s12094-016-1525-x. Epub 2016 Aug 4. Review.

PMID:
27492014
20.

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC).

Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18.

21.

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.

Ahmed M, Dorling L, Kerns S, Fachal L, Elliott R, Partliament M, Rosenstein BS, Vega A, Gómez-Caamaño A, Barnett G, Dearnaley DP, Hall E, Sydes M, Burnet N, Pharoah PD, Eeles R, West CM.

Br J Cancer. 2016 May 10;114(10):1165-74. doi: 10.1038/bjc.2016.94. Epub 2016 Apr 12.

22.

Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272].

López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, Maldonado X, Gómez Iturriaga A, Casas F, González San Segundo C.

Rep Pract Oncol Radiother. 2016 Jan-Feb;21(1):90-2. doi: 10.1016/j.rpor.2015.06.006. Epub 2015 Jul 20.

23.

Surgery for Stage IIIA Non-Small-cell Lung Cancer: Lack of Predictive and Prognostic Factors Identifying Any Subgroup of Patients Benefiting From It.

Jeremić B, Casas F, Dubinsky P, Gomez-Caamano A, Čihorić N, Videtic G.

Clin Lung Cancer. 2016 Mar;17(2):107-12. doi: 10.1016/j.cllc.2015.11.001. Epub 2015 Nov 11. Review.

PMID:
26683387
24.

Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain.

Gómez Caamaño A, Zapatero A, López Torrecilla J, Maldonado X.

Clin Transl Oncol. 2016 Sep;18(9):884-92. doi: 10.1007/s12094-015-1454-0. Epub 2015 Nov 30.

PMID:
26621508
25.

No Role For Trimodality Therapy and Consolidation Chemotherapy Compared With Concurrent Radiochemotherapy Alone in Stage III Non-Small-Cell Lung Cancer.

Jeremic B, Cihoric N, Casas F, Gomez-Caamaño A, Dubinsky P.

J Clin Oncol. 2016 Jan 10;34(2):196-7. doi: 10.1200/JCO.2015.63.5037. Epub 2015 Nov 16. No abstract available.

PMID:
26573074
26.

The Trimodality Treatment Approach in Stage III/pN2 Non-Small Cell Lung Cancer: "Usually Appropriate" May Well be a Very Inappropriate Treatment Option.

Jeremic B, Casas F, Dubinsky P, Cihoric N, Gomez-Caamano A.

Am J Clin Oncol. 2015 Dec;38(6):645. doi: 10.1097/COC.0000000000000223. No abstract available.

27.

Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.

López-Torrecilla J, Boladeras A, Cabeza MA, Zapatero A, Jove J, Esteban LM, Henriquez I, Casaña M, González-San Segundo C, Gómez-Caamaño A, Mengual JL, Hervás A, Muñoz JL, Sanz G.

Strahlenther Onkol. 2015 Oct;191(10):792-800. doi: 10.1007/s00066-015-0866-7. Epub 2015 Jul 9.

PMID:
26156249
28.

Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.

López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, Maldonado X, Gómez Iturriaga A, Casas F, González San Segundo C.

Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):259-72. doi: 10.1016/j.rpor.2015.04.003. Epub 2015 May 30. Review. Erratum in: Rep Pract Oncol Radiother. 2016 Jan-Feb;21(1):90-2.

29.

Imaging of Tumor Angiogenesis for Radiologists--Part 1: Biological and Technical Basis.

García-Figueiras R, Padhani AR, Beer AJ, Baleato-González S, Vilanova JC, Luna A, Oleaga L, Gómez-Caamaño A, Koh DM.

Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):407-24. doi: 10.1067/j.cpradiol.2015.02.010. Epub 2015 Mar 6. Review.

PMID:
25890454
30.

Imaging of Tumor Angiogenesis for Radiologists--Part 2: Clinical Utility.

García-Figueiras R, Padhani AR, Beer AJ, Baleato-González S, Vilanova JC, Luna A, Oleaga L, Gómez-Caamaño A, Koh DM.

Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):425-36. doi: 10.1067/j.cpradiol.2015.02.009. Epub 2015 Mar 6. Review.

PMID:
25863438
31.

The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.

Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, Pesqueira D, Tabernero A, Gómez Veiga F, Lorente JA, Porras M, Lobato JJ, Ribal MJ, Planas J; ANAMET Investigators Group.

J Urol. 2015 Jun;193(6):1963-9. doi: 10.1016/j.juro.2014.12.086. Epub 2014 Dec 23.

PMID:
25541340
32.

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.

Zapatero A, González San Segundo C, Boladeras A, Gómez Caamaño A, López Torrecilla J, Maldonado X.

Clin Transl Oncol. 2015 Mar;17(3):223-9. doi: 10.1007/s12094-014-1217-3. Epub 2014 Sep 3.

PMID:
25183050
33.

A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.

Fachal L, Gómez-Caamaño A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, Kerns SL, Sánchez-García M, Lobato-Busto R, Dorling L, Elliott RM, Dearnaley DP, Sydes MR, Hall E, Burnet NG, Carracedo Á, Rosenstein BS, West CM, Dunning AM, Vega A.

Nat Genet. 2014 Aug;46(8):891-4. doi: 10.1038/ng.3020. Epub 2014 Jun 29.

PMID:
24974847
34.

No association between typical European mitochondrial variation and prostate cancer risk in a Spanish cohort.

Fachal L, Gómez-Caamaño A, Alvarez Iglesias V, Gómez Carballa A, Calvo P, Salas A, Vega A.

J Hum Genet. 2014 Jul;59(7):411-4. doi: 10.1038/jhg.2014.46. Epub 2014 Jun 5.

PMID:
24898828
35.

A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.

Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM.

Radiother Oncol. 2014 May;111(2):178-85. doi: 10.1016/j.radonc.2014.02.012. Epub 2014 Apr 28.

PMID:
24785509
36.

Evaluating the role of mitochondrial DNA variation to the genetic predisposition to radiation-induced toxicity.

Fachal L, Mosquera-Miguel A, Gómez-Caamaño A, Sánchez-García M, Calvo P, Lobato-Busto R, Salas A, Vega A.

Radiother Oncol. 2014 May;111(2):199-205. doi: 10.1016/j.radonc.2014.03.012. Epub 2014 Apr 17.

PMID:
24746576
37.

Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer.

López Torrecilla J, Zapatero A, Herruzo I, Calvo FA, Cabeza MA, Palacios A, Guerrero A, Hervás A, Lara P, Ludeña Martínez B, Del Cerro Peñalver E, Nagore G, Sancho G, Mengual JL, Mira M, Mairiño A, Samper P, Pérez S, Castillo I, Martínez Cedrés JC, Ferrer E, Rodriguez S, Maldonado X, Gómez Caamaño A, Ferrer C; Grupo de Investigación GICOR-URONCOR-SEOR.

Clin Transl Oncol. 2014 May;16(5):447-54. doi: 10.1007/s12094-013-1121-2. Epub 2013 Oct 25.

PMID:
24682792
38.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.

Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30.

39.

Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.

Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H.

Radiother Oncol. 2013 Jun;107(3):372-6. doi: 10.1016/j.radonc.2013.05.001. Epub 2013 May 26.

40.

CT perfusion in oncologic imaging: a useful tool?

García-Figueiras R, Goh VJ, Padhani AR, Baleato-González S, Garrido M, León L, Gómez-Caamaño A.

AJR Am J Roentgenol. 2013 Jan;200(1):8-19. doi: 10.2214/AJR.11.8476. Review.

PMID:
23255736
41.

Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.

Fachal L, Gómez-Caamaño A, Peleteiro P, Carballo A, Calvo-Crespo P, Sánchez-García M, Lobato-Busto R, Carracedo A, Vega A.

Radiother Oncol. 2012 Dec;105(3):321-8. doi: 10.1016/j.radonc.2012.09.013. Epub 2012 Oct 15.

PMID:
23075580
42.

TGFβ1 SNPs and radio-induced toxicity in prostate cancer patients.

Fachal L, Gómez-Caamaño A, Sánchez-García M, Carballo A, Peleteiro P, Lobato-Busto R, Carracedo A, Vega A.

Radiother Oncol. 2012 May;103(2):206-9. doi: 10.1016/j.radonc.2012.01.015. Epub 2012 Mar 3.

PMID:
22385796
43.

[Prognostic factors and functional imaging in rectal cancer].

García Figueiras R, Caro Domínguez P, García Dorrego R, Vázquez Martín A, Gómez Caamaño A.

Radiologia. 2012 Jan-Feb;54(1):45-58. doi: 10.1016/j.rx.2011.05.017. Epub 2011 Oct 14. Spanish.

44.

BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data.

Fachal L, Gómez-Caamaño A, Celeiro-Muñoz C, Peleteiro P, Blanco A, Carballo A, Forteza J, Carracedo A, Vega A.

Prostate. 2011 Dec;71(16):1768-79. doi: 10.1002/pros.21394. Epub 2011 Apr 25.

PMID:
21520156
45.

Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.

Balboa E, Duran G, Lamas MJ, Gomez-Caamaño A, Celeiro-Muñoz C, Lopez R, Carracedo A, Barros F.

Pharmacogenomics. 2010 Jun;11(6):747-61. doi: 10.2217/pgs.10.51.

PMID:
20504250

Supplemental Content

Loading ...
Support Center